Yves Horsmans, MD; Michel De Clercq, MD; Christine Sempoux, MD
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
Horsmans Y., De Clercq M., Sempoux C.; Venlaxafine-Associated Hepatitis. Ann Intern Med. 1999;130:944. doi: 10.7326/0003-4819-130-11-199906010-00014
Download citation file:
Published: Ann Intern Med. 1999;130(11):944.
TO THE EDITOR:
Venlafaxine is a second-generation antidepressant agent approved for use in the United States in 1993 (1, 2). It is a derivative of phenethylanine and is structurally unrelated to first- and other second-generation antidepressant agents. Elevations of liver enzyme levels has rarely been described (2). We report the first case of acute hepatitis after venlafaxine administration.
A 44-year-old woman was seen for acute hepatitis on 23 March 1998. Results of liver function tests done in September 1997 at the time of the introduction of venlafaxine therapy (150 mg/d) were normal. For several months the patient had also been taking lormetazepam and trazodone for her depression. She had undergone hysterectomy in 1996 for a fibroma. On 9 March 1998, blood tests were performed by her general practitioner because of severe asthenia. Findings included an alanine aminotransferase level of 1082 U/L (normal, <56 U/L) and an aspartate aminotransferase level of 661 U/L (normal, <40 U/L).
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only